Literature DB >> 20232204

Non-barrier agents for postoperative adhesion prevention: clinical and preclinical aspects.

Atsushi Imai1, Hiroshi Takagi, Kazutoshi Matsunami, Noriko Suzuki.   

Abstract

PURPOSE: The purpose of this document is to review the non-barrier methods to prevent postoperative adhesion formation in humans.
METHODS: A MEDLINE computer search was performed to identify relevant articles using the keywords "postoperative adhesion prevention" "abdominal" and "humans". Subsequent searches were performed using the keyword "non-barrier" to further supplement the information obtained. After careful review of the abstracts, 15 articles were selected for inclusion in the manuscript.
RESULTS: Many methods, drugs and materials have been demonstrated effective for reducing postoperative adhesion in animal models. Among them, four types of drugs have been clinically used in attempts to reduce postoperative adhesions: gonadotropin-releasing hormone agonists, anti-inflammatory drugs, humidified CO(2) and hydroflotation. Many clinical and meta-analyses revealed that hydroflotation materials do not increase adhesion-free outcome. GnRHa pretreatment using a standard clinical dose (3.75 mg monthly) before myomectomy do not decrease adhesion formation. The role of CO(2) on the reduction and/or prevention of postoperative adhesions have been reported only in cardiac surgery. None of them have been adopted for clinical standard therapy, despite positive reports in animals or preclinical applications.
CONCLUSION: In contrast to the results from animal studies, there is no substantial evidence that the use of non-barrier materials reduces postoperative abdominal adhesions in humans.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20232204     DOI: 10.1007/s00404-010-1423-3

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  1 in total

1.  Comparative study for preventive effects of intra-abdominal adhesion using cyclo-oxygenase-2 enzyme (COX-2) inhibitor, low molecular weight heparin (LMWH), and synthetic barrier.

Authors:  Yong Il Kim
Journal:  Yonsei Med J       Date:  2013-11       Impact factor: 2.759

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.